SFDA Approves Winrevair For Treating Pulmonary Arterial Hypertension In Adults

The Saudi Food and Drug Authority (SFDA) has given the green light to register Winrevair (Sotatercept) as an orphan drug. This approval is part of the SFDA Orphan Drug Program, targeting pulmonary arterial hypertension (PAH) in adults classified under WHO Functional Class II to III. The goal is to enhance exercise capacity for these patients.

PAH is a severe condition where lung blood vessels thicken, leading to increased pressure in the pulmonary arteries. Symptoms often include breathlessness, chest discomfort, and fatigue. These symptoms can significantly impact daily life and physical activity levels.

Sotatercept operates through a unique mechanism by inhibiting activin, a protein that contributes to vessel thickening and elevated blood pressure in the lungs. By blocking activin, Sotatercept improves lung blood flow and reduces pressure, enhancing patients' ability to engage in physical activities and improving their quality of life.

The SFDA's approval followed a thorough assessment of Sotatercept's effectiveness and safety according to regulatory standards. Clinical trials showed a significant decrease in disease progression risk and mortality among PAH patients in WHO Functional Class II or III. The safety profile was deemed acceptable, with common side effects like headaches, nosebleeds, and skin itching.

The SFDA is dedicated to ensuring access to effective treatments for rare diseases that often lack adequate options. The Orphan Drug Program is a strategic initiative supporting pharmaceutical innovation and addressing unmet medical needs. This aligns with Saudi Vision 2030's aim to improve healthcare quality.

Orphan Drug Program Objectives

An orphan drug treats rare conditions affecting fewer than five people per 10,000 in Saudi Arabia. The program encourages developing such drugs by providing incentives for pharmaceutical companies. This initiative helps bridge gaps in treatment availability for rare diseases.

For more details on the Orphan Drugs Guideline, visit the SFDA website or contact them via email at [email protected].

With inputs from SPA